Acetyl Salicylate
Phase 3Small molecule
Acetyl Salicylate is one of 37 small molecule programs targeting Brain Aneurysm. It is currently in Phase 3.
2
Indications
2
Total Trials
0
Active Trials
36
Competitors
Pipeline
Status by Indication[3][1]
Competition
Competitive Landscape
430 competitors in Ischemic Stroke
#DrugCompanyPhaseTrials
1Acetyl Salicylate
UUniversity of Calgary
Phase 3
Proamatine
TakedaPreclinical
Levaquin
WWim Janssens
Preclinical
Tylenol
KKenvue Brands
Preclinical
Solu-Medrol
MMassachusetts Eye and Ear Infirmary
Preclinical
Xylocaine
CCitius Pharmaceuticals, Inc.
Preclinical
Statins
SanofiPreclinical
Urokinase
Mmedac GmbH
Preclinical
Drug Therapy
MMassachusetts General Hospital
Preclinical
Ginkgo Biloba Extract
NNational Center for Complementary and Integrative Health (NCCIH)
Preclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Clinical
Trials by Indication[1]
Brain Aneurysm1 trial
Ischemic stroke1 trial
Prevalence of Aspirin Resistance in Ischemic Stroke Patients at Assiut University Hospital
Unknown status·—··NCT05151263·133 enrolled
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for Acetyl Salicylate. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Phase 3[1]
- Company
- UUniversity of Calgary